Synopsis: Alembic Pharmaceuticals has received final approval from the USFDA for Haloperidol Tablets used in the treatment of psychotic disorders and Tourette’s Disorder. The approved product addresses a market opportunity of approximately $27 million in the United States and further strengthens the company’s growing US generics portfolio.
Shares of Alembic Pharmaceuticals Limited are likely to remain in focus after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Haloperidol Tablets, USP, in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
Alembic Pharmaceuticals has a total market capitalization of Rs. 14,470.98 crore. The company’s shares were trading at Rs. 735.60 apiece during Thursday’s trading session.
According to the company’s exchange filing, the approved product is therapeutically equivalent to Haldol Tablets of Ortho McNeil Pharmaceutical. Haloperidol Tablets are prescribed for the management of psychotic disorders and for controlling tics and vocal utterances associated with Tourette’s Disorder in both children and adults.
The approval is significant because the product has an estimated market size of approximately $27 million for the twelve months ended March 2026, according to IQVIA data. The approval provides Alembic an opportunity to expand its presence in the US generics market and generate incremental revenues from a regulated pharmaceutical segment.
Why is approval important?
The US market remains one of the largest and most profitable pharmaceutical markets globally. Every USFDA approval strengthens a company’s product portfolio and provides additional opportunities for revenue diversification.
For Alembic, the approval adds another product to its growing generics basket and reinforces its execution capabilities in the highly regulated US market. A broader portfolio also helps pharmaceutical companies reduce dependence on individual products and improve long-term business stability.
With this latest approval, Alembic Pharmaceuticals has received a cumulative total of 240 ANDA approvals from the USFDA, comprising 221 final approvals and 19 tentative approvals.
A strong approval pipeline is often considered a key indicator of future growth potential for pharmaceutical companies, as it provides visibility into upcoming product launches and revenue opportunities.
Industry outlook
The global generic pharmaceutical market continues to benefit from patent expiries, increasing healthcare accessibility, and rising demand for cost-effective medicines. Indian pharmaceutical companies remain among the largest suppliers of generic drugs to the US market, supported by strong manufacturing capabilities and competitive cost structures.
Going forward, product approvals, new launches, regulatory compliance, and pipeline expansion will remain key factors influencing Alembic Pharmaceuticals’ growth prospects and financial performance.
Business overview
Alembic Pharmaceuticals Limited is engaged in the development, manufacturing, and marketing of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). The company operates a vertically integrated business model supported by three research and development facilities and five manufacturing facilities.
Founded in 1907, Alembic is one of India’s established pharmaceutical companies and has built a significant presence across domestic and international markets. The company continues to focus on expanding its specialty and generic product portfolio while strengthening its footprint in regulated markets such as the United States.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
